Bimekizumab (IL-17A and IL-17Fi) 3 year safety and efficacy in PsA Phase IIb trial
⭐️no new safety signals
⭐️candida infections were all mild/moderate
⭐️efficacy consistent and maintained
Abs#491
#ACR21
@RheumNow
https://t.co/BK6xPMqAEM https://t.co/meoPd7k0Xp
Links:
Bimekizumab Long-Term Safety and Efficacy in Patients with Ankylosing Spondylit…
https://bit.ly/3kdPpBp
06-11-2021
